High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma

Haematologica

Volumn 87, Issue 10, 2002, Pages 1028-1035

  Salar, Antonio ^a   Martino, Rodrigo ^a   Perea, Granada ^a   Ribera, José Maria ^a   López Guillermo, Armando ^a   Guardia, Ramón ^a   Escoda, Lourdes ^a   Altés, Albert ^a   Sierra, Jorge ^a   Montserrat, Emili ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Ifosfamide; Lymphoma; Salvage therapy; Transplantation

Indexed keywords

CARMUSTINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHYLPREDNISOLONE;

ADULT; ALOPECIA; ARTICLE; AUTOTRANSPLANTATION; BACTEREMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MALE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR REGRESSION; URINARY TRACT INFECTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; METHYLPREDNISOLONE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 0036797148     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1023-30.
2. Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:2656-75.
3. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998; 25:483-91.
4. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-22.
5. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994; 12:1169-76.
6. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18:3633-42.
7. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13:1734-41.
8. Rodriguez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep 1978; 62:493-7.
9. Case DC, Anderson J, Ervin TJ, Gottlieb A. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552. Med Pediatr Oncol 1988; 16:182-6.
10. Hagemeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma 1999; 34:433-41.
11. King K, Younes A. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma. Semin Oncol 2000; 27:14-22.
12. Cabanillas FC, Hagemeister FB, Bodey GP, Freireich EJ. IMPV-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60:693-7.
13. Doorduijn JK, Spruit P, van Der Holt B, van't Veer M, Budel L, Lowenberg B, et al. Etoposide, mitoxantrone and prednisone: A salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. Haematologica 2000; 85:814-9.
14. Hickish T, Roldan A, Cunningham D, Mansi J, Ashley S, Nicolson V, et al. EPIC: An effective low toxicity regimen for relapsing lymphoma. Br J Cancer 1993; 68:599-604.
15. Goss P, Shepherd F, Scott JG, Baker M, Sutton D, Sutcliffe S. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphoma. Leuk Lymphoma 1994; 18:123-9.
16. Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995; 6:609-11.
17. Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer 1996; 77:2302-7.
18. Baars JW, Holtkamp MJ, Nooyen WJ, Walll EV, Te Velde A, Dalesio O, et al. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours. Anticancer Res 1996; 16:3089-95.
19. Haim N, Ben Shadar M, Faraggi D, Tsuri-Etzioni, Leviov M, Epelbaum R. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer 1997; 80:1989-96.
20. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776-85.
21. Mayer J, Koristek Z, Vasova I, Vorlicek J, Vodvarka P. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Bone Marrow Transplant 1999; 23:413-9.
22. Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87:816-21.
23. McBride NC, Ward MC, Mills MJ, Eden AG, Hughes A, Cavenagh JD, et al. EPIC as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to BEAM high dose chemotherapy and peripheral blood progenitor cell transplantation. Leuk Lymphoma 1999; 35:339-45.
24. van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, et al. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant 2001; 27:397-404.
25. Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F, et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10:1615-23.
26. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-5.
27. Meehan KR, Pritchard RS, Leichter JW, Littenberg B, Welch HG. Autologous bone marrow transplantation versus chemotherapy in relapsed non-Hodgkin's lymphoma: Estimates of long-term survival from the recent literature. Am J Hematol 1995; 50:116-26.
28. Salar A, Sierra J, Gandarillas M, Caballero MD, Marin J, Lahuerta JJ, et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: The role of preparative regimens. Bone Marrow Transplant 2001; 27:405-12.
29. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary M, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.
30. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10:1419-32.
31. Salar A, Martino R, Altés A, Sureda A, Brunet S, Sierra J. High-dose ifosfamide and etoposide plus methylprednisolone for refractory or relapsed aggessive non-Hodgkin's lymphoma. Haematologica 2000; 85:217-9.
32. Gaspard MH, Maraninchi D, Stoppa AM, Gastaut JA, Michel G, Tubiana N, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: Toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22:256-62.
33. Cabanillas F. The battle against refractory lymphomas: Guerrilla warfare and star wars? Cancer Invest 1990; 8:107-9.
34. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
36. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc (A) 1972; 135:185-206.
37. Anonymous. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-94.
38. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34:187-202.
39. Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A, et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5:1340-7.
40. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:588-95.
41. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11:1846-51.
42. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups. Br J Haematol 1996; 92:880-9.
43. Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24:271-7.
44. Cortelazzo S, Rambaldi A, Rossi A, Oldani E, Ghielmini M, Benedetti F, et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 2001; 114:333-41.
45. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42.
46. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 1998; 92:3562-8.
47. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial. J Clin Oncol 1998; 16:48-55.
48. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: An intention-to-treat analysis. Blood 2000; 96:2399-404.